Cross Country Healthcare to be Acquired by Knox Lane at $13.25 per Share

What happened

Cross Country Healthcare announced an all-cash acquisition by Knox Lane for $13.25 per share, valuing the company at $437 million. The offer represents a 46% premium to the prior closing price of $9.06 and exceeds the DeepValue report's base-case valuation of $12.00. The deal provides a clear exit for shareholders, bypassing the uncertainty around the company's recovery from the travel nursing downturn. Knox Lane, a growth-oriented investment firm, plans to take the company private, ending the failed Aya merger saga. The transaction is expected to close in the second half of 2026, subject to shareholder approval and regulatory clearance.

Implication

The acquisition crystallizes value at $13.25, which is above the standalone fair value range of $12-$15. While the deal removes downside risk, shareholders cannot benefit from a potential recovery beyond $13.25. Those holding should tender shares to capture the premium. The deal underscores the attractiveness of CCRN's platform to private equity, but also highlights the difficulty of executing a turnaround as a public company. Long-term oriented investors may consider selling now unless they believe a higher bid emerges, which appears unlikely given the definitive agreement.

Thesis delta

Previously, the thesis centered on a cyclical recovery and buyback support with upside to $12-$15 if revenue stabilized. The acquisition at $13.25 confirms that value exists but removes the speculative upside from a standalone turnaround. Investors should now focus on deal execution and timing rather than operating metrics, as the stock will trade in line with the offer price until closing.